Third Harmonic Bio Inc (THRD) Return on Assets ROA from the first quarter of 2025 to first quarter of 2024 and for the year 2025, Average High and Low, Fundamental Ratios from Mar 31 2025 to Mar 31 2024 - CSIMarket
CSIMarket Company Name, Ticker, Suppliers, else..
 


• ROA Quarterly
• ROI Quarterly
• ROE Quarterly
Third Harmonic Bio Inc   (NASDAQ: THRD)


Third Harmonic Bio Inc 's ROA from the first quarter of 2025 to the first quarter of 2024 and 5 Year Period

Return on Assets, Quarterly Results, Trends, Rankings, Statistics


What is Third Harmonic Bio Inc 's ROA in the first quarter of 2025?
Third Harmonic Bio Inc achieved a return on average assets (ROA) of 18.86 % in its first quarter of 2025, this is above THRD's average return on assets of 10.69%.
Third Harmonic Bio Inc assets over the 12 months ending in its first quarter of 2025 are valued at $283 million

ROA has improved compared to 16.19% in the fourth quarter of 2024, due to net income growth.

However, within the Healthcare sector 47 other companies had a higher return on assets. While Return on assets, overall ranking has advanced in the Mar 31 2025 quarter, so far to 259, from total ROA ranking in the fourth quarter of 2024 at 360.

What is ROA?


Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

Return On Assets (Mar 31 2025)
I. Quarter		 (Dec 31 2024)
IV. Quarter		 (Sep 30 2024)
III. Quarter		 (Jun 30 2024)
II. Quarter		 (Mar 31 2024)
I. Quarter
Y / Y Total Assets Change 3.87 % 6.21 % 7.66 % -6.81 % -6.97 %
Y / Y Net Income Change 101.55 % 91.73 % 87.92 % 41.63 % -13.53 %
Net Income (TTM) in million 53 45 39 33 30
Return On Assets (TTM) 18.86 % 16.19 % 14.18 % 12.07 % 10.72 %
THRD's Total Ranking # 259 # 360 # 397 # 532 # 586
Total Assets (TTM) in million 278 292 301 262 268
Seq. Total Assets Change -4.65 % -3.22 % 14.86 % -2.01 % -2.5 %
Seq. Net Income Change 20.81 % -5.01 % 28.88 % 36.29 % 14.92 %

THRD's 5 Years Annual ROA >> Back to THRD Management Effectiveness >> Compare THRD ROA to its Competitors


Return On Assets Company Ranking
Within: No.
Industry # 19
Sector # 48
Overall # 252

Return On Assets Statistics
High Average Low
18.67 %
10.69 %
4.32 %
(Mar 31 2025)   (Sep 30 2023)



  News about Third Harmonic Bio Inc Return on Assets ROA

Analyzing Third Harmonic Bios Financial Performance and Strategic Engagement in the Biopharmaceutical Sector

In the rapidly evolving field of biopharmaceuticals, companies must navigate various challenges, from financial performance to investor relations. Third Harmonic Bio, Inc. (Nasdaq: THRD) stands out as a clinical-stage company dedicated to addressing inflammatory diseases affecting the dermal, respiratory, and gastrointestinal systems. Recent developments surrounding the company reflect both its aspirations and the realities of financial performance in a competitive healthcare environment. Corporate Strategy and Investor Engagement On August 26, 2024, Third Harmonic Bio announced that its Chief Executive Officer, Natalie Holles, would participate in an upcoming fireside chat during several major investor conferences. This strategic move aims to bolster investor confidence, increase visibility within the pharmaceutical sector, and communicate the company’s long-term vision for innovative treatments targeting serious inflammatory conditions.



Financial Statements
Third Harmonic Bio Inc 's Assets $ 278 million THRD's Balance sheet
Third Harmonic Bio Inc 's Income $ 16 million Quarterly THRD's Income Statement
THRD's Income by Division See THRD's Income by Division



Annual Return On Assets (Dec 31 2024)
FY 2024		 (Dec 31 2023)
FY 2023		 (Dec 31 2022)
FY 2022
FY
FY
Y / Y Total Assets Change 6.21 % -6.87 % - - -
Total Assets in million 292 275 295 0 0
Y / Y Net Income Change 47.51 % -12.32 % - - -
Net Income in million 45 31 35 0 0
Annual Return On Assets 15.59 % 11.22 % 11.92 % - -

THRD's 5 Years Annual ROA >> Back to THRD Management Effectiveness >> Compare THRD ROA to its Competitors



Comment on THRD's ROA in the fiscal year ending 2024
In the fiscal year 2024 ROA improved to 15.59 % compared to prior year, due to annual net income growth of 47.51 % to $45.47 million, while value of Third Harmonic Bio Inc 's overall assets grew just by 6.21 % to $291.67 million, compared to $291.67 a year before.


More Return On Assets Ratios
THRD's' Return on Assets at Yahoo Finance
Major Pharmaceutical Preparations Industry Return On Assets Trends and Statistics
Healthcare Sector Roa Statistics
Roa Trends for overall market
THRD's Roa Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and overall Market
Highest Ranking Return On Assets
Lowest Ranking Return On Assets
Subscribers only: Roa for THRD's Competitors
Subscribers only: Roa for Third Harmonic Bio Inc 's Suppliers
Subscribers only: Return On Assets for THRD's Customers

You may also want to know
THRD's Roi THRD's Inventory Turnover Ratio THRD's Growth Rates THRD's Dividend Comparisons
THRD's Profitability Ratios THRD's Asset Turnover Ratio THRD's Dividend Growth
THRD's Roe THRD's Valuation Ratios THRD's Financial Strength Ratios THRD's Dividend Payout Ratio



Companies with similar Return On Assets at Mar 31 2025, within Healthcare Sector ROA
Exelixis Inc   51.45 %
Stablecoin Development Corporation  50.36 %
Synlogic Inc   47.83 %
Adma Biologics Inc   46.83 %
Agios Pharmaceuticals Inc   46.06 %
Pharmacyte Biotech Inc   44.19 %
Gridai Technologies Corp  43.94 %
Medinotec Inc   40.68 %
Sbc Medical Group Holdings Incorporated  40.28 %
Dariohealth Corp   38.41 %
Seres Therapeutics Inc   36.27 %
Longduoduo Co Ltd  34.93 %
Edwards Lifesciences Corporation  33.98 %
Cytomx Therapeutics Inc   32.17 %
Bluebird Bio Inc   31.57 %
Novavax inc   29.99 %
Ptc Therapeutics inc   29.31 %
Nutriband Inc   27.24 %
Idexx Laboratories Inc  26.97 %
Mettler toledo International Inc   26.04 %
Hims and Hers Health Inc   24.52 %
Rigel Pharmaceuticals Inc  24.47 %
Catalyst Pharmaceuticals Inc   24.37 %
Halozyme Therapeutics Inc   23.26 %
Whitehawk Therapeutics Inc   22.47 %
Siga Technologies Inc  22.07 %
Acadia Pharmaceuticals Inc   21.74 %
Medpace Holdings Inc   20.81 %
Carlisle Companies Incorporated  20.64 %
Iradimed Corporation  20.60 %

Date modified: 2026-09-08T15:11:30+00:00


Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.